<!--StartFragment-->

**AMR in Cancer Epidemiology : A Growth Concern for Global Health**

<!--StartFragment-->

Author : Khanh Gia Duong

Introduction : 

Antimicrobial resistance (AMR) is a global health crisis with far-reaching implications across multiple domains, including cancer. The intersection of AMR and cancer poses a significant challenge, as infections caused by resistant pathogens can complicate treatment, increase mortality, and strain healthcare resources.

Addressing the Threat of Antimicrobial Resistance in Cancer Care: Implications for Patients and Public Health

AMR can complicate the management of cancer patients by limiting the effectiveness of antimicrobial agents used in cancer treatment. For example, chemotherapy-induced immunosuppression can increase the risk of infections in cancer patients, and the presence of AMR can lead to treatment failures and adverse outcomes. In a study by Minichil Worku et al. (2022), it was found that cancer patients with bloodstream infections caused by high risk for antibiotic-resistant bacterial infections had a significantly elevated risk of infection-related death 

Furthermore, AMR can also impact cancer screening and diagnosis. The accuracy of diagnostic tests and the effectiveness of screening programs may be compromised if infections associated with AMR are not properly identified and treated. This can result in delays in cancer diagnosis and treatment, leading to poorer outcomes for cancer patients.

In addition, AMR in cancer epidemiology can have broader implications for public health, including the spread of resistant pathogens within healthcare settings and communities. The overuse and misuse of antibiotics in cancer treatment and supportive care can contribute to the selection and dissemination of resistant strains, posing a significant risk to vulnerable populations. If the scientific community fails to manage and replenish our antibiotic supply, nearly 10 million extra deaths are predicted by 2050 due to drug-resistant infections. ( Amila K. Nanayakkara PhD et al 2021) Effective infection control measures, antimicrobial stewardship programs, and collaboration between healthcare providers are essential to mitigate the impact of AMR on cancer patients and the general population.

Conclusion

AMR in cancer epidemiology presents a growing challenge that significantly impacts patient outcomes and healthcare systems. The increasing prevalence of resistant infections in cancer patients underscores the need for comprehensive strategies to prevent and manage AMR in oncology. By prioritizing research and implementing effective control measures, the medical community can improve the quality of care for cancer patients, ultimately enhancing their chances of successful treatment. The intersection of AMR and cancer underscores the importance of ongoing vigilance and innovation in the face of evolving health threats.

Reference : 

Worku M, Belay G, Tigabu A (2022). Bacterial profile and antimicrobial susceptibility patterns in cancer patients. PLoS ONE 17(4): e0266919. <https://doi.org/10.1371/journal.pone.0266919>

Amila K. Nanayakkara PhD, Helen W. Boucher MD, Vance G. Fowler Jr MD, MHS, Amanda Jezek, Kevin Outterson JD, LLM, David E. Greenberg MD (2021). Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward.CA: A Cancer Journal for Clinicians, 7(6), 488-504 <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21697>

<!--EndFragment-->

<!--EndFragment-->
